sparfloxacin (AT 4140)

07/01/2010 - "The analysis of the treatment results allows the conclusion that sparfloxacin is highly effective in urethrocystitis associated with intracellular infections. "
01/01/2002 - "Sparfloxacin (once daily for 7-14 days) was highly effective in the infection management according to clinical and bacteriological results (83.7 per cent and 78.1 per cent subsequently)."
08/01/1989 - "AT-4140 showed good oral efficacy against systemic infections with Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, and Pseudomonas aeruginosa in mice. "
11/01/1996 - "We investigated whether the fluoroquinolone sparfloxacin is effective in treating MAC infection in the murine macrophage-like cell line J774. "
08/01/1993 - "Sparfloxacin (SPFX), a new oral quinolone antimicrobial, was evaluated for the clinical efficacy against skin/soft tissue structural and osteomyelitic infections. "

08/01/1994 - "Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice."
01/01/1998 - "Clinical efficacy of sparfloxacin in mycoplasmal pneumonia: a pilot study."
01/01/1998 - "[Clinical study on sparfloxacin (SPFX) in the treatment of mycoplasmal pneumonia and penetration of SPFX to the pneumonic lesion]."
05/01/1996 - "This study demonstrated that sparfloxacin given once daily is a suitable therapy for the treatment of community-acquired pneumonia in the elderly or in patients with failure of previous antibiotic therapy."
05/01/1996 - "Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies."

06/01/2001 - "In MDR-TB patients, sparfloxacin, along with other anti-tuberculosis drugs, appears to be effective and safe. "
04/01/2001 - "In summary, sparfloxacin proved an effective and safe alternative antituberculosis drug for complicated tuberculosis."
07/01/2011 - "tuberculosis and the compounds showing similar type of binding patterns with that of the existing drug molecules, like sparfloxacin, were finally reported. "
07/01/1999 - "Treatment of tuberculosis--role of sparfloxacin?"
07/01/1999 - "Sparfloxacin in tuberculosis."

06/01/2009 - "Disposition kinetic studies of sparfloxacin were investigated in healthy as well as hepatopathic and nephropathic birds after a single intravenous administration at 40 mg / kg body weight. "
03/01/1996 - "Animals (n = 12) in the study group received sparfloxacin, 25 mg/kg body weight every 12 h intravenously. "
11/01/1990 - "For the pharmacokinetic study, sparfloxacin was given (10 mg/kg of body weight) to infected guinea pigs by the intraperitoneal route; peak levels in serum and lung were 2.6 micrograms/ml and 1.6 micrograms/g, respectively, at 1 h, with a terminal-phase half-life of elimination from serum of 5 h.(ABSTRACT TRUNCATED AT 250 WORDS)"
06/01/1998 - "However, five of eight rats treated with a single oral dose of 1,800 mg of sparfloxacin/kg of body weight showed typical cartilage lesions in the femoral part of the knee joint. "
05/01/1997 - "Seventy-two hours after injection of 0.1 ml (10(6) cfu/ml) of an Escherichia coli suspension into the right epididymis via the right ductus deferens, a single oral dose of sparfloxacin 50 mg/kg body weight was administered. "

05/01/1996 - "A total of 2081 adult patients with community-acquired lower respiratory tract infections participated in Phase III clinical trials of sparfloxacin. "
11/01/1995 - "The aim of this work was to study the in vitro activity of sparfloxacin against bacteria isolated from patients with community acquired respiratory infections between October 1994 and January 1995. "
05/01/1999 - "Sparfloxacin is a suitable therapeutic alternative for the empiric treatment of respiratory tract infections owing to its favorable pharmacokinetic profile and activity against typical and atypical respiratory tract pathogens, even in geographic areas with a high incidence of penicillin resistance."
01/01/1998 - "Since sparfloxacin displays an excellent activity against Mycoplasma pneumoniae and has a broad spectrum of antimicrobial activity against not only Gram-negative bacteria but also Gram-positive bacteria, Legionella, Chlamydia and acid-fast bacteria, it appears to be useful as the drug of first choice in the treatment of respiratory tract infections."
11/01/1997 - "Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections."